NCT04003909

Brief Summary

ESP block advantages include its simplicity, easy identifiable ultrasonographic landmarks and low risk for serious complications as injection is into tissue plane that is distant from pleura, major blood vessels and discrete nerves. Coupled with the fact that the erector spinae muscle and ESP extend down to the lumbar spine, ESP block was hypothesized to be performed at the level of L4. In a recent case report, ultrasound guided ESP block was successfully performed at L4 transverse process level for postoperative analgesia after total hip arthroplasty. However, confirmation of the efficacy of ESP block in hip replacement surgeries needed more investigation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable postoperative-pain

Timeline
Completed

Started Jul 2019

Shorter than P25 for not_applicable postoperative-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 26, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 1, 2019

Completed
4 days until next milestone

Study Start

First participant enrolled

July 5, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 5, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 6, 2019

Completed
Last Updated

November 7, 2019

Status Verified

November 1, 2019

Enrollment Period

3 months

First QC Date

June 26, 2019

Last Update Submit

November 5, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total morphine consumption

    Total morphine consumption in rescue boluses during 1st 24 hrs postoperatively.

    24 hours postoperative

Secondary Outcomes (3)

  • Visual analogue scale

    30 minutes,2,4, 6, 12, and 24 hours postoperative.

  • Duration of analgesia

    24 hours postoperative

  • Incidence of complications

    24 hours

Study Arms (2)

ESP group

EXPERIMENTAL

patients will have ultrasound guided ESP block before spinal anesthesia.

Procedure: ultrasound-guided Erector spinae plane blockProcedure: subarachonoid block

Control group

EXPERIMENTAL

patients will have spinal Anesthesia without ESP block

Procedure: subarachonoid block

Interventions

The patients will be in lateral position. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. Local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle will be inserted inplane to the ultrasound beam in a cranial-to-caudal direction until contact made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total volume of 20ml bupivicaine 0.25% and 20 ml xylocaine 1% will be injected into the ESP on the affected side.

ESP group

Local anesthesia 2ml of lidocaine 2% will be applied intradermally to the needle entrance point. A 22-G block needle will be inserted, free cerebrospinal fluid flow will be observed and 20mg of hyperbaric bupivacaine 0.5% and 10μg of fentanyl will be injected for 30 seconds.

Control groupESP group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged from 40 to 65 years old
  • Both sexes.
  • ASA I-II.
  • Undergo hip replacement surgery.
  • Body mass index (BMI) from 18 to 35 kg/m2.

You may not qualify if:

  • Patient refusal.
  • Contraindication to regional anesthesia (bleeding disorder, use of any anticoagulants, local infection, etc. )
  • BMI \> 35.
  • Known allergy to local anesthetics.
  • ASA III-IV.
  • Patients with difficulty in evaluating their level of pain.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anesthesia Department

Cairo, 1772, Egypt

Location

Related Publications (4)

  • Tulgar S, Selvi O, Senturk O, Ermis MN, Cubuk R, Ozer Z. Clinical experiences of ultrasound-guided lumbar erector spinae plane block for hip joint and proximal femur surgeries. J Clin Anesth. 2018 Jun;47:5-6. doi: 10.1016/j.jclinane.2018.02.014. Epub 2018 Mar 6. No abstract available.

    PMID: 29522966BACKGROUND
  • Ueshima H, Otake H. RETRACTED: Clinical experiences of ultrasound-guided erector spinae plane block for thoracic vertebra surgery. J Clin Anesth. 2017 May;38:137. doi: 10.1016/j.jclinane.2016.12.028. Epub 2017 Feb 17. No abstract available.

    PMID: 28372654BACKGROUND
  • Hamilton DL, Manickam B. Erector spinae plane block for pain relief in rib fractures. Br J Anaesth. 2017 Mar 1;118(3):474-475. doi: 10.1093/bja/aex013. No abstract available.

    PMID: 28203765BACKGROUND
  • Tulgar S, Kapakli MS, Senturk O, Selvi O, Serifsoy TE, Ozer Z. Evaluation of ultrasound-guided erector spinae plane block for postoperative analgesia in laparoscopic cholecystectomy: A prospective, randomized, controlled clinical trial. J Clin Anesth. 2018 Sep;49:101-106. doi: 10.1016/j.jclinane.2018.06.019. Epub 2018 Jun 15.

    PMID: 29913392BACKGROUND

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Ashraf Rady, M.D.

    Cairo University

    PRINCIPAL INVESTIGATOR
  • Amr abdelnasser

    Cairo University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
associate professor

Study Record Dates

First Submitted

June 26, 2019

First Posted

July 1, 2019

Study Start

July 5, 2019

Primary Completion

October 5, 2019

Study Completion

November 6, 2019

Last Updated

November 7, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share

Locations